Stay updated with breaking news from Kronos Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HC Wainwright reaffirmed their buy rating on shares of Kronos Bio (NASDAQ:KRON – Get Rating) in a research note released on Tuesday morning, TipRanks reports. They currently have a $36.00 target price on the stock. Separately, Piper Sandler lowered their price objective on Kronos Bio from $50.00 to $30.00 and set an overweight rating on […]
10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM ... | March 7, 2022
“The whole build process is much faster and much easier for everyone involved.” With Vault EDC, Kronos Bio streamlined the study...
Kronos Bio, Inc. , a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today reported recent business progress and fourth-quarter and full-year 2021... | February 24, 2022
Pfizer picks from Roche's executive team, snagging pharma early R&D leader William Pao as the Big Pharma's next chief development officer. Leo Pharma poaches from ... a Danish meme stock for its new CEO, who will lead a reorganization of the dermatology biopharma. And Sio Gene Therapies CEO Cheruvu is out the door as Parkinson's program also hits the exit.